Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (cohort visit planners) and reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
- We will ring you to check your suitability and provide further information about the study
- We will make you a screening appointment at NZCR Christchurch. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
New Zealand Clinical Research is trialling an experimental medication that is a treatment for pulmonary arterial hypertension (PAH).
REGN13335 is an antibody. An antibody is a kind of protein that your immune (defence) system normally makes to fight bacteria and viruses. Scientists can now make antibodies in the laboratory and produce them for the treatment of many different diseases. REGN13335 is designed to bind and inactivate a protein called PDGF-B. PDGF-B binds to certain cells, causing them to multiply. PDGF-B may play a role in certain diseases, including PAH.
It is an investigational drug because it has not been approved by MedSafe or other drug regulatory authorities.
This study (2023 FULL 18573) is being funded by Regeneron and has been approved by the Health and Disability Ethics Committee.
Study Candidates
- Be aged 18 – 55 years.
- Are in good health.
- Have a BMI (Body Mass Index) between 18.0 kg/m2 – 32.0 kg/m2
- Not currently taking any regular prescription medications for your health (e.g., anti-depressants)
- Are a non-smoker and/or non-vaper for at least 3 months
What is Involved?
Study Participation: 2 night stay + 10 outpatient appointments
Reimbursement: $4,700 (less tax)